Traditional clinical trials are slow, expensive, and often non-representative.

In this episode, we explore “Revolutionizing Clinical Trials: A Manifesto for AI‑Driven Transformation,” a new collaborative vision from pharma, consultancies, and researchers. The paper proposes a transformative roadmap—using causal models and digital twins—to make trials smarter, more efficient, and deeply personalized, all while working within the current regulatory landscape.

We dive into:

• The promise of causal inference for identifying responsive subgroups with precision

• How digital twin simulations can predict outcomes and optimize trial design

• Real-world implications for speed, safety, and scaling

• What regulatory and ethical guardrails are needed for clinical implementation

If new AI tools are going to reshape drug discovery and clinical research, this is where the battleground lies.